August 2, 2022

Cimerli™ (ranibizumab-eqrn) from Coherus BioSciences has been approved as the first interchangeable biosimilar to Lucentis (ranibizumab injection). Cimerli is used to treat neovascular (wet) age-related macular degeneration (AMD)

  • Cimerli is used to treat macular edema (swelling) caused by diabetes or by a blockage in the blood vessels. it is also used to treat diabetic retinopathy, the most common cause of vision loss in people with diabetes.
  • Usual Adult Dose for Macular Degeneration:
    • 5 mg via intravitreal injection once a month (approximately 28 days)
    • Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. Patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly.
    • Use: Neovascular (wet) age-related macular degeneration (AMD)
  • Usual Adult Dose for Macular Edema Following Retinal Vein Occlusion (RVO):
    • 5 mg via intravitreal injection once a month (approximately 28 days)
    • Use: Macular edema following retinal vein occlusion (RVO)
  • Usual Adult Dose for Diabetic Macular Edema (DME):
    • 3 mg via intravitreal injection once a month (approximately 28 days)
    • Use: Diabetic macular edema (DME)
  • Usual Adult Dose for Diabetic Retinopathy:
    • 3 mg via intravitreal injection once a month (approximately 28 days)
    • Use: Diabetic retinopathy
  • Usual Adult Dose for Myopic Choroidal Neovascularization (mCNV):
    • 5 mg via intravitreal injection once a month (approximately 28 days) for up to three months. Patients may be retreated if needed
    • Use: Myopic choroidal neovascularization (mCNV)
  • No pricing information has been made available, but an October launch is anticipated.
August 18, 2022

U.S. FDA Approves First Cetrotide Generic

Read More
August 17, 2022

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

Read More